Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06050122 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
A Phase 3 study of Gorlin Syndrome, sponsored by Sol-Gel Technologies.
- Active
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT06050122: Active Phase 3 study of Gorlin Syndrome, sponsored by Sol-Gel Technologies.
NCT06050122 is a Phase 3 study of Gorlin Syndrome that is active but no longer recruiting, run by Sol-Gel Technologies. The registered enrollment target is 140 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06050122, a Phase 3 study of Gorlin Syndrome, is active but no longer recruiting, sponsored by Sol-Gel Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.
Primary Outcome
New BCCs at Month 12 in the Patidegib Gel 2% and Vehicle Gel groups, as assessed by the CPRB
Conditions Studied
Interventions
- DRUG Patidegib Topical Gel
- DRUG Patidegib Topical Gel with no active patidegib
Study Locations (20)
California
- Center for Dermatology Clinical Research - Fremont
- University of California Los Angeles (UCLA) - Center for Inflammatory Bowel Diseases - Westwood Location - Los Angeles
- The Dermatology Center of Newport - Newport Beach
- Stanford University - Lucille Packard's Children's Hospital - Redwood City
Ohio
- Apex Clinical Research Center - Canton
- Cleveland Clinic - Main Campus - Cleveland
- Apex Clinical Research Center - Mayfield Heights
Florida
- Dermatology Associates of Tallahassee - Tallahassee
- University of South Florida Health - Tampa
Arkansas
- Northwest Arkansas Clinical Trials Center - Rogers
Connecticut
- Yale University - New Haven
Illinois
- The University of Chicago Medicine - Chicago
Maryland
- The Johns Hopkins Hospital - Baltimore
Michigan
- University of Michigan Health - Michigan Medicine - University Hospital - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-03-17 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
What the registry record for NCT06050122 still lists
NCT06050122 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Gorlin Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Patidegib Topical Gel is the first listed.
NCT06050122 names 20 study sites across 14 states, led by California, Ohio, Florida.
Frequently Asked Questions
What is clinical trial NCT06050122 about?
NCT06050122 is a clinical study titled "Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome". The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with...
What is the current status of trial NCT06050122?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2024-03-17. Estimated completion is 2026-08.
What conditions does trial NCT06050122 study?
This clinical trial studies the following conditions: Gorlin Syndrome.
What interventions are being tested in trial NCT06050122?
The interventions under investigation include: Patidegib Topical Gel (DRUG), Patidegib Topical Gel with no active patidegib (DRUG).
Who is sponsoring clinical trial NCT06050122?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06050122 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06050122's enrollment target sits among peer trials
140 1566th of 2000 higher than 424 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI